SUBSCRIBE
SUBSCRIBE
News   Drug Development

Viewpoint Molecular Targeting(R) Presents Preclinical Data from VMT-

December 21, 2021 | 
1 min read

Viewpoint Molecular Targeting, Inc. announced the presentation of preclinical data from its theranostic in development, VMT-

  • Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors
  • Preclinical data of VMT-
Preclinical
ACCESS Newswire
MORE ON THIS TOPIC
IN PARTNERSHIP WITH DIA
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
 · 
1 min read
 · 
Lori Ellis
Computational Biology - The Study of Biological Systems Through Computational Techniques and Modeling - Conceptual Illustration
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
 · 
4 min read
 · 
Annalee Armstrong
Brain with pills, Alzheimer awareness day, dementia diagnosis, Parkinson disease, memory loss disorder, damaged mind
Huntington’s disease
PTC Nosedives Despite Claiming Phase II Win for Huntington’s Hopeful
May 5, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Vaccine and syringe injection. Doctor hand with syringe. Vaccination of people for prevention, immunization and treatment from virus infection. Medicine, flu shot, test with needle. Vector
Policy
HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past
May 1, 2025
 · 
3 min read
 · 
Heather McKenzie